Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Long-Term Deferred Tax (2019 - 2025)

Historic Long-Term Deferred Tax for Cresco Labs (CRLBF) over the last 7 years, with Q3 2025 value amounting to $12.4 million.

  • Cresco Labs' Long-Term Deferred Tax fell 2687.08% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 2687.08%. This contributed to the annual value of $13.1 million for FY2024, which is 1368.32% up from last year.
  • According to the latest figures from Q3 2025, Cresco Labs' Long-Term Deferred Tax is $12.4 million, which was down 2687.08% from $12.8 million recorded in Q2 2025.
  • In the past 5 years, Cresco Labs' Long-Term Deferred Tax ranged from a high of $17.6 million in Q2 2024 and a low of $26000.0 during Q4 2022
  • Its 5-year average for Long-Term Deferred Tax is $10.4 million, with a median of $11.1 million in 2023.
  • Per our database at Business Quant, Cresco Labs' Long-Term Deferred Tax tumbled by 9960.37% in 2022 and then soared by 4431153.85% in 2023.
  • Quarter analysis of 5 years shows Cresco Labs' Long-Term Deferred Tax stood at $6.6 million in 2021, then crashed by 99.6% to $26000.0 in 2022, then surged by 44311.54% to $11.5 million in 2023, then rose by 13.68% to $13.1 million in 2024, then decreased by 5.75% to $12.4 million in 2025.
  • Its Long-Term Deferred Tax was $12.4 million in Q3 2025, compared to $12.8 million in Q2 2025 and $12.9 million in Q1 2025.